BeSt Treatment Strategies. A randomized clinical trial to test the effectiveness of different treatment-strategies in patients with early rheumatoid arthritis. Long term follow-up.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22114

Enrollment

500

Registered

2005-09-08

Start date

2004-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients continue treatment according to the treatment group they were allocated to at the beginning of the BeSt trial. All treatment adjustments will continue to be based on threemonthly DAS measurements, aiming at DAS =<2.4 (or <1.6 before medication may be stopped altogether).

Interventions

Continued treatment with established antirheumatic drugs according to accepted treatment strategies, with threemonthly treatment adjustments dictated by the height of the DAS: if DAS>2.4, than medicat

Eligibility

Inclusion criteria

Inclusion criteria: All patients who completed participation in the first 2 years of BeSt.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
1. Functional ability as measured by HAQ; 2. Radiological damage as measured by Sharp/van der Heijde score of hands and feet; 3. Side effects and extra-articular manifestations (as reported and as monitored through laboratory assessments, X-rays, DEXAs).	—

Secondary

Measure	Time frame
1. Quality of life; 2. Utilities; 3. Work participation; 4. Costs.	—

Contacts

Public ContactC.F. Allaart

Leiden University Medical Center (LUMC), Department of Rheumatology, C1-39, P.O. Box 9600

c.f.allaart@lumc.nl+31 (0)71 5263598

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)